Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients

By A. Kamphorst, R. Pillai, Shu Yang, T. Nasti, Rama S. Akondy, A. Wieland, G. Sica, Ke Yu, Lydia Koenig, N. Patel and 9 more. Proceedings of the National Academy of Sciences of the United States of America, 2017

748 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/5eb7b12ed5fc497f3c646424ab9efa97b6975749

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Oncology

Citations in the corpus

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors (2018, background): “And peripheral PD-1Ki-67CD8 T cell was detected to express more activation-associated markers such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and inducible T cell costimulator (ICOS) [95].”
Organoid modeling of the tumor immune microenvironment (2018, background): “…expand intratumoral exhausted-like CD8+ T cells via primary action on peripheral versus tumor-infiltrating populations since PD-1 blockade increases exhausted-like TILs (Wei et al., 2017) but also proliferation of peripheral blood PD-1+ CD8+ T cells (Huang et al., 2017; Kamphorst et al., 2017).”
CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer. (2019, background): “Indeed, several groups have demonstrated that in response to PD-1 or CTLA-4 blockade in humans, Tex cells are a—if not the—major responding immune cell type (26, 296, 297).”